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Abstract We show here that the YIL113w gene of Saccharo-
myces cerevisiae encodes a functional protein phosphatase.
Yil113p shows no activity in vitro towards either phosphorylated
casein or myelin basic protein. However, Yil113p dephosphor-
ylates activated extracellular signal-regulated kinase 2 MAP
kinase indicating that it is a dual-speci¢city MAP kinase phos-
phatase. In support of this we ¢nd that Yil113p speci¢cally
interacts with the stress-activated Slt2/Mpk1p MAP kinase of
S. cerevisiae. Furthermore, expression of Yil113p causes the
dephosphorylation of Slt2/Mpk1p in vivo, while expression of
an inactive mutant of Yil113p causes the accumulation of phos-
phorylated Slt2/Mpk1p. We conclude that the physiological tar-
get of YIL113p is Slt2/Mpk1p. * 2002 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
The mitogen-activated protein kinases (MAPKs) are key
components of cellular signal transduction pathways which
are activated in response to a wide variety of extracellular
stimuli and act to relay, amplify and integrate complex signals
in order to elicit appropriate physiological responses [1]. The
budding yeast Saccharomyces cerevisiae has ¢ve distinct
MAPK signalling cascades which are involved in mediating
diverse physiological functions [2]. Fus3p and Kss1p are in-
volved in the mating response to pheromone and the regula-
tion of pseudohyphal/invasive growth respectively. Slt2/
Mpk1p and Hog1p are stress-activated MAPKs which medi-
ate cell integrity and the response to osmotic stress respec-
tively while Smk1/Sps1p is required for spore wall morpho-
genesis [2,3].
The magnitude and duration of MAPK signalling are
known to be critical determinants of biological outcome
[4,5] and it is now clear that the MAPK itself is a major target
for regulation through the action of speci¢c protein phospha-
tases. MAPK activation is uniquely dependent on the phos-
phorylation of both threonine and tyrosine residues within the
‘activation loop’ of the kinase and dephosphorylation of ei-
ther residue is su⁄cient for inactivation. This can be achieved
by protein-tyrosine phosphatases (PTPs), serine/threonine-spe-
ci¢c phosphatases or by dual-speci¢city (threonine/tyrosine)
protein phosphatases. Work in a variety of model systems,
including both budding and ¢ssion yeast, has demonstrated
that all three classes of enzyme are involved [6].
Thus far it has been demonstrated that two tyrosine-speci¢c
phosphatases, Ptp2p and Ptp3p, are involved in regulating
MAPK signalling in S. cerevisiae. These enzymes were ¢rst
implicated in the regulation of the Hog1p pathway in response
to osmotic stress [7,8]. Subsequently it was shown that both
Ptp2p and Ptp3p also regulate Fus3p [9]. Interestingly, Fus3p
had already been identi¢ed as a target for negative feedback
regulation by the pheromone inducible dual-speci¢city phos-
phatase Msg5p [10] and was therefore the ¢rst example of a
MAPK which is regulated by both a dual-speci¢city and one
or more tyrosine-speci¢c phosphatases [9]. More recently both
Msg5p and Ptp2p/Ptp3p have been implicated in the dephos-
phorylation of Slt2/Mpk1p indicating that the participation of
multiple classes of protein phosphatase in the regulation of a
single MAPK is more widespread [11,12].
The completion of the genomic sequence of S. cerevisiae has
facilitated the complete annotation of the yeast proteome and
allowed targeted surveys of the extent of particular protein
families, revealing many previously unidenti¢ed proteins
[13]. A database search using the nucleotide sequence of the
human dual-speci¢city MAPK phosphatase Pyst1/MAPK
phosphatase (MKP)-3 [14] as a probe revealed signi¢cant ami-
no acid sequence homology with an open reading frame
(ORF) designated YIL113w located on chromosome 9. The
YIL113w ORF encodes a putative protein of 209 amino acids
which contains a single copy of the consensus sequence for the
PTP active site. This coupled with the fact that the closest
relative of YIL113w within the S. cerevisiae genome is
MSG5 (56% identity), indicates that this protein might play
a role in regulating MAPK signalling in yeast. Here we dem-
onstrate that YIL113w encodes a functional protein phospha-
tase which speci¢cally interacts with and inactivates the Slt2/
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Mpk1p MAPK in vivo. Our data strongly suggest that the
physiological target of Yil113p is the stress-activated Slt2/
Mpk1p MAPK.
2. Materials and methods
2.1. Yeast strains
AYS927 (MATa/MATK ade2-1/ade2-1 his3-11,15/his3-11,15 leu2-
3,112/leu2-3,112 trp1-1/trp1-1 ura3-1/ura3-1 can1-100/can1-100 ssd1-
d2/ssd1/d2 Galþ) ; PJ69-4A (MATa trp1-901 leu2-3,112 ura3-52 his3-
200 gal4v gal80v LYS2: :GAL1-HIS3 GAL2-ADE2 met2: :GAL7-
lacZ) ; PJ69-4K (MATK trp1-901 leu2-3,112 ura3-52 his3-200 gal4v
gal80v LYS2: :GAL1-HIS3 GAL2-ADE2 met2: :GAL7-lacZ) (kindly
provided by Dr P. James, University of Wisconsin, USA).
2.2. Plasmids
All manipulations were performed using standard techniques and
plasmid structures were veri¢ed by DNA sequencing [15]. The
YIL113w ORF was ampli¢ed by PCR using yeast genomic DNA
(strain AYS927) as template and subcloned into the bacterial expres-
sion vector pET15b (Novagen, Madison, WI, USA) as an XhoI^Bam-
HI fragment. The codon specifying cysteine 140 within YIL113w was
mutated to serine by overlap extension PCR [16] using yeast genomic
DNA as template and the mutant ORF was subcloned into pET15b
as above. The Slt2/Mpk1 ORF was ampli¢ed by PCR using yeast
genomic DNA (strain AYS927) as template and subcloned into
pET15b as an NdeI^XhoI fragment. For expression of myc-tagged
Slt2/Mpk1p and Hog1p in bacteria, the ORFs were ampli¢ed by
PCR as above using primers which deleted the stop codon and intro-
duced a single copy of the myc epitope tag followed by a stop codon
and XhoI site and subcloned into pET15b as NdeI^XhoI fragments.
For yeast two-hybrid assays the MAPKs FUS3,KSS1,SLT2/MPK1
and SMK1/SPS1 were ampli¢ed by PCR using yeast genomic DNA
(strain AYS927) as template and subcloned into pGBKT7 (Clontech,
Palo Alto, CA, USA) as either an EcoRI^BamHI (FUS3,KSS1 and
SLT2MPK1) or an XmaI^BamHI (SMK1/SPS1) fragment. A ‘kinase
dead’ mutant of HOG1 in which the codon specifying an essential
aspartic acid (residue 162) was mutated to asparagine was created
by overlap extension PCR [16] using yeast genomic DNA (strain
AYS927) as template and subcloned into pGBKT7 as an NdeI^Bam-
HI fragment. Wild-type YIL113w and its corresponding cysteine 140
to serine mutant were subcloned into pGADT7 (Clontech, Palo Alto,
CA, USA) as BamHI^XhoI fragments. Plasmids pGBD-C1 encoding
SNF1 fused to the GAL4 DNA-binding domain and pGAD-C1 en-
coding SNF4 fused to the GAL4 activation domain were kindly pro-
vided by S. Fields (University of Washington, Seattle, WA, USA).
Wild-type YIL113w and its corresponding cysteine 140 to serine
mutant were subcloned as HindIII^BamHI fragments into a modi¢ed
yeast expression vector, pYES2 (Invitrogen, Carlsbad, CA, USA) en-
coding a C-terminal myc tag (pYES2.8myc). The MSG5 ORF was
ampli¢ed by PCR using yeast genomic DNA (strain AYS927) as
template and subcloned into pYES2.8myc as a SacI^BamHI frag-
ment. The codon specifying cysteine 319 within MSG5 was mutated
to serine by overlap extension PCR [16], using yeast genomic DNA as
template and the mutant ORF was subcloned into pYES2.8myc as
above.
2.3. Expression and puri¢cation of recombinant Yil113p, Yil113pC140S,
Slt2p/Mpk1p and Hog1p
pET15b expression plasmids encoding His-tagged Yil113p,
Yil113pC140S, Slt2/Mpk1p, Slt2/Mpk1p-myc and Hog1p-myc were
transformed into the host bacterial strain BL21 (DE3) (Novagen,
Madison, WI, USA) using standard techniques. Following expression,
proteins were puri¢ed using nickel^agarose resin (Ni2þ-nitriloacetate;
Qiagen Inc., Valencia, CA, USA) under either native (Yil113p) or
denaturing (Slt2/Mpk1p and Hog1p) conditions in accordance with
the manufacturers instructions. Recombinant proteins were analysed
by SDS^PAGE followed by staining with Coomassie blue.
2.4. Co-immunoprecipitations
Anti-myc monoclonal antibody (9B11, Cell Signalling, Beverly,
MA, USA) was coupled to protein-G Sepharose overnight. Coupled
antibody was then incubated for 1 h at 4‡C either alone or with 1 Wg
of either recombinant Slt2/Mpk1p-myc or Hog1p-myc. Recombinant
Yil113p (1 Wg) was then added and incubated for a further 1 h at 4‡C
before centrifugation at 16 000Ug for 1 min. Finally, immunoprecipi-
tates were washed three times with CB100 bu¡er (20 mM HEPES, pH
8.0, 0.2 mM EDTA, 100 mM KCl, 1 mM DTT, 20% v/v glycerol and
0.1% v/v NP-40) and analysed by SDS^PAGE and Western blotting.
2.5. Phosphatase assays
Phosphatase activity of either recombinant Yil113p or Yil113pC140S
was determined using p-NPP hydrolysis exactly as described previ-
ously [14]. For inhibitor studies, reactions were supplemented with
either 2 mM sodium orthovanadate (Sigma Aldrich St. Louis, MO,
USA), 1 WM okadaic acid (Calbiochem, La Jolla, CA, USA) or 1 WM
microcystin (Calbiochem, La Jolla, CA, USA). Catalytic activation
was assessed by adding the indicated amounts of either recombinant
Slt2/Mpk1p or extracellular signal-regulated kinase 2 (ERK2)
MAPKs. Preparation of 32P-labelled myelin basic protein (MBP)
and casein and protein phosphatase assays using these substrates
have been described previously [17]. Dephosphorylation of ERK2
by Yil113p in vitro was assayed using using rabbit polyclonal anti-
bodies speci¢c for either pThr183-ERK2 (Promega Corp., Madison,
WI, USA) or pTyr185-ERK2 (Calbiochem, La Jolla, CA, USA) ex-
actly as described previously [18].
2.6. Yeast two-hybrid analysis
Plasmids encoding GAL4 DNA-binding domain and GAL4 activa-
tion domain fusion proteins were transformed into the S. cerevisiae
strains PJ69-4A and PJ69-4K respectively, exactly as described previ-
ously [19]. Following mating of these strains two-hybrid interactions
were quanti¢ed in the resulting diploids by activation of the lacZ
reporter using a cell permeable L-galactosidase assay, according to
the method described by Guarente et al. [20]. At least three indepen-
dent two-hybrid assays were performed for each interaction studied
and, following correction for background activities (GAL4 DNA-
binding domain fusion and GAL4 activation domain alone), mean
values with associated standard errors are presented. Expression of
GAL4 DNA-binding domain and GAL4 activation domain fusion
proteins was veri¢ed by Western blotting of whole cell extracts pre-
pared from yeast diploids using monoclonal antibodies which recog-
nise either the Gal4p DNA-binding domain or the Gal4p activation
domain respectively (Clontech, Palo Alto, CA, USA).
2.7. Monitoring the activation of endogenous Slt2/Mpk1p using
anti-phospho p44/42 MAPK antibodies
Yeast strain AYS927 was transformed with either empty pYES2 or
pYES2.8myc containing each of the following ORFs: YIL113w,
yil113wC140S, MSG5 and msg5C319S. Cells were then grown at 25‡C
in SC plus ra⁄nose (minus uracil) to an absorbance at 600 nm of 0.3^
0.4. Galactose was then added to a ¢nal concentration of 2% w/v and
cells were incubated at 25‡C for a further 2 h to induce protein ex-
pression. Yeasts were either left untreated or exposed to heat shock at
39‡C for 30 min before lysis and clari¢cation of protein extracts as
described by Kamada et al. [21]. Equal amounts of total yeast protein
(10^15 Wg) for each sample were analysed by SDS^PAGE. Activated
Slt2/Mpk1p was detected by Western blotting using an antibody
against phosphorylated ERK1/2 MAPK (NEB, Beverly, MA, USA)
as described previously [12]. Expression of myc-tagged Yil113p,
Yil113pC140S, Msg5p and Msg5pC319S was detected by Western blot-
ting using the anti-myc (9E10) monoclonal antibody. Levels of total
Slt2/Mpk1p in yeast cell extracts were analysed by Western blotting
using an antibody against Slt2/Mpk1p (sc-6802, Santa Cruz Biotech,
CA USA).
3. Results
3.1. YIL113w encodes a functional protein phosphatase
Yil113p was expressed as a His-tagged fusion protein and
puri¢ed using nickel^agarose resin. A mutant protein
Yil113pC140S, in which the predicted PTP active site cysteine
was substituted by serine (Cys140 to Ser) was also produced
under identical conditions (Fig. 1A). Yil113p is catalytically
active as it readily hydrolyses p-NPP. Furthermore, this activ-
ity is absolutely dependent on the cysteine residue within the
PTP active site as Yil113pC140S is inactive (Fig. 1B). Finally,
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Yil113p is inhibited by the PTP inhibitor sodium orthovana-
date but its activity is una¡ected by addition of either micro-
cystin or okadaic acid, which are speci¢c inhibitors of type 1/2
serine/threonine phosphatases (Fig. 1C).
The prototypic dual-speci¢city phosphatase of vaccinia vi-
rus (VH1) was ¢rst characterised by its ability to dephosphor-
ylate protein substrates modi¢ed on either tyrosine or serine
residues [22]. To determine if Yil113p has a similar activity we
examined its ability to dephosphorylate casein (modi¢ed on
serine/threonine residues) and MBP (modi¢ed on tyrosine res-
idues). As positive controls for these reactions we used PP2A,
a type-2 serine/threonine phosphatase, and PTP1B, a tyrosine-
speci¢c phosphatase respectively. We could detect no measur-
able liberation of [32P] from either of these two model sub-
strates on incubation with recombinant Yil113p under condi-
tions where either PP2A (casein) or PTP1B (MBP) readily
dephosphorylated these proteins (Fig. 2A,B). This strongly
suggests that YIL113p is highly speci¢c for its physiological
substrate and is reminiscent of the activity of the mammalian
dual-speci¢city MKP, CL100/MKP-1, which was also without
activity towards either casein or MBP but readily dephos-
phorylated ERK2 MAPK in vitro [17].
To determine whether Yil113p has activity towards
MAPKs, activated ERK2 was incubated with Yil113p and
Fig. 1. Expression and characterisation of recombinant Yil113p protein in vitro. A: Expression of His-tagged Yil113p in Escherichia coli. Coo-
massie stained SDS^PAGE gel of soluble protein fractions from uninduced (lane 1) and induced (lane 2) bacteria expressing wild-type Yil113p.
Yil113p (lane 3) and Yil113pC140S proteins (lane 4) after puri¢cation using nickel^agarose resin. B: The Yil113p protein possesses intrinsic phos-
phatase activity. The indicated amount of either puri¢ed Yil113p (b) or Yil113pC140S (a) was assayed for its ability to hydrolyse p-NPP.
C: The phosphatase activity of Yil113p is inhibited by sodium vanadate. The indicated amount of puri¢ed Yil113p was assayed for its ability
to hydrolyse p-NPP either in the absence (b) or presence of 1 WM okadaic acid (a), 1 WM microcystin (E) or 2 mM sodium vanadate (O).
Fig. 2. Yil113p is a functional dual-speci¢city MAPK phosphatase in vitro. A: Yil113p is unable to dephosphorylate tyrosine residues on
MBP. The indicated amount of either PTP1B (left panel) or Yil113p (right panel) was incubated with 32P-labelled MBP and hydrolysis of phos-
photyrosine was determined by measuring the release of acid-soluble counts (cpm) using scintillation counting. B: Yil113p is unable to dephos-
phorylate serine/threonine residues on casein. The indicated amount of Yil113p was incubated with 32P-labelled casein and hydrolysis of phos-
phoserine/threonine (cpm) was determined by measuring the release of acid-soluble counts (cpm) using scintillation counting. The point on the
X-axis (a) shows the number of counts released on a single incubation of this substrate with the catalytic subunit of PP2A (120 WU) over the
time course of this assay. C: Dephosphorylation of recombinant activated ERK2 by Yil113p in vitro. Immunoblot of activated ERK2 protein
following incubation with the indicated amount of recombinant Yil113p. The blot was probed with an anti-ERK2 antibody as a loading con-
trol (upper panel) and then with antibodies which speci¢cally recognise either the phosphorylated tyrosine (middle panel) or threonine (lower
panel) residues within the conserved T-E-Y motif of ERK2. As a positive control ERK2 was also incubated with 12.5 Wg of recombinant
Pyst1/MKP-3 protein (lane 6).
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the phosphorylation state of the ERK2 was analysed using
antibodies which speci¢cally recognise either the phospho-
threonine or phosphotyrosine residues within the Thr-Xaa-
Tyr motif. Our results clearly show that recombinant
Yil113p acts directly on ERK2 causing signi¢cant dephos-
phorylation of both phosphotyrosine and phosphothreonine
(Fig. 2C). This activity is signi¢cantly lower than is seen on
incubation with the ERK-speci¢c human dual-speci¢city
MKP Pyst1/MKP-3 (see Fig. 2C, lane 4) and Yil113p prefer-
entially dephosphorylates the tyrosine residue of ERK2. This
probably re£ects the fact that mammalian ERK2 is a poor
model for the S. cerevisiae MAPK which is the physiological
target of Yil113p. However, we can conclude that Yil113p is
able to act as a bona-¢de dual-speci¢city MAPK phosphatase
in vitro.
3.2. Yil113p interacts speci¢cally with the Slt2/Mpk1p MAPK
in S. cerevisiae
The inactivation of mammalian MAPKs by dual-speci¢city
MKPs is accompanied by the formation of a physical complex
between phosphatase and substrate [6]. To determine whether
Yil113p is capable of speci¢c protein^protein interactions with
the ¢ve MAPKs of S. cerevisiae in vivo we have used a yeast
two-hybrid assay.
We were unable to demonstrate any interactions between
Yil113p and either Fus3p, Kss1p, Hog1pD162N or Smk1/Sps1p
irrespective of whether Yil113p or each of the individual
MAPKs were used as the ‘bait’ in these assays. However,
the Slt2/Mpk1p MAPK showed a strong interaction with
Yil113p when used as a ‘bait’ in the two-hybrid system as
revealed by semi-quantitative L-galactosidase assays (Fig.
3A). Slt2/Mpk1 also interacted strongly with the inactive
Cys140 to Ser mutant Yil113pC140S under these conditions
(Fig. 3A). Our failure to detect any interaction between
Yil113p and the other yeast MAPK isoforms is not due to
a lack of expression during these assays as veri¢ed by Western
blotting (Fig. 3B). The interaction between Yil113p and Slt2/
Mpk1p is both direct and speci¢c as recombinant Yil113p co-
immunoprecipitates with recombinant myc-tagged Slt2/
Mpk1p but not myc-tagged Hog1p in vitro (Fig. 4A).
3.3. Yil113p does not undergo catalytic activation on incubation
with MAPKs
A signi¢cant breakthrough in our understanding of MKP
function came with the discovery that the catalytic activity of
the mammalian dual-speci¢city MKP Pyst1/MKP-3 could be
speci¢cally increased on binding to ERK2 MAPK in vitro
[23]. Catalytic activation has subsequently been demonstrated
to be a general property of these enzymes and is thought to be
an important mechanism which underpins substrate selectivity
[24,25]. To determine whether Yil113p is activated in this way,
p-NPP hydrolysis was monitored either in the absence or
presence of either ERK2 MAPK or Slt2/Mpk1p, the speci¢c
binding partner for Yil113p in S. cerevisiae (Fig. 4B). Our
results show that the catalytic activity of recombinant
Yil113p is unchanged upon incubation with either of these
Fig. 3. Analysis of two-hybrid interactions between Yil113p and the
MAPKs of S. cerevisiae. A: Yil113p selectively interacts with the
Slt2/Mpk1p MAPK in vivo. Plasmids encoding GAL4 DNA-binding
domain (‘bait’) fusions of each of the MAPKs Fus3p, Kss1p, Slt2/
Mpk1p, Smk1/Sps1p and hog1pD162N were transformed into yeast
strain PJ69-4A while plasmids encoding either the Yil113p or
Yil113pC140S (Slt2/Mpk1p only) GAL4 activation domain fusion pro-
teins were transformed into the S. cerevisiae strain PJ69-4K. Follow-
ing mating, two-hybrid interactions were quanti¢ed in the resulting
diploids by activation of the lacZ reporter using a cell permeable
L-galactosidase assay. At least three independent two-hybrid assays
were performed for each interaction studied and following correc-
tion for background activities, mean values with associated standard
errors are presented. As a positive control in these assays the well
characterised interaction between the yeast proteins Snf4p and
Snf1p was used. B: Western blot analysis showing expression of
GAL4 DNA-binding domain (‘bait’) fusions of each of the MAPKs
in yeast diploids using an antibody against the Gal4p DNA-binding
domain (K-Gal4p-DBD, left panel). PJ69-4A/K control (lane 1),
Gal4pDBD control (lane 2), Fus3p (lane 3) Kss1p (lane 4), Slt2/
Mpk1p (lane 5) and Smk1/Sps1 (lane 6). Expression of Yil113p
GAL4 activation domain (‘prey’) fusion protein using an antibody
against the Gal4p activation domain (K-Gal4p-AD, middle panel).
PJ69-4A/K control (lane 7), Gal4pAD control (lane 8), Yil113p
(lane 9). Expression of Yil113pC140S GAL4 activation domain
(‘prey’) fusion protein (K-Gal4p-AD, right panel). PJ69-4A/K control
(lane 10), Gal4pAD control (lane 11), Yil113pC140S (lane 12).
Fig. 4. The interaction between Yil113p and Slt2/Mpk1p is speci¢c
and direct but the phosphatase activity of Yil113p is not increased
upon incubation with recombinant MAPK. A: Recombinant
Yil113p was incubated alone or with either myc-tagged Mkp1p or
myc-tagged Hog1p before immunoprecipitation using an anti-myc
monoclonal antibody. Immunoprecipitates were then analysed by
SDS^PAGE and Western blotting using a polyclonal antibody
against Yil113p (lower panel). B: The indicated amount of puri¢ed
Yil113p was assayed for its ability to hydrolyse p-NPP either in the
absence (b) or presence of either 20 Wg of recombinant ERK2 (a)
or 10 Wg of recombinant Slt2/Mpk1 (E).
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proteins suggesting that speci¢c interaction between Yil113p
and Slt2/Mpk1p may be su⁄cient for the substrate selectivity
of this phosphatase.
3.4. Yil113p dephosphorylates Slt2/Mpk1p in vivo
An antibody which speci¢cally recognises the phosphorylat-
ed (activated) form of ERK2 MAPK also recognises phos-
phorylated Slt2/Mpk1p in S. cerevisiae [12]. To determine if
Yil113p was able to dephosphorylate Slt2/Mpk1p in vivo both
myc-tagged wild-type and Yil113pC140S were expressed in
S. cerevisiae using the galactose-inducible yeast expression
vector pYES2. pYES2 containing either myc-tagged wild-
type or a cysteine to serine mutant of Msg5p were used as
positive controls for these experiments. These expression plas-
mids along with empty pYES2 vector were then transformed
into yeast, grown at 25‡C in medium containing galactose to
induce the expression of either Yil113p or Msg5p and either
left untreated or exposed to a 39‡C heat shock for 30 min.
The phosphorylation state of endogenous Slt2/Mpk1p and the
expression of the myc-tagged phosphatases was then moni-
tored by Western blotting. In agreement with previously pub-
lished data, our results show that the activation of endoge-
nous Slt2/Mpk1p in response to heat shock can be monitored
using the anti-phospho ERK antibody (Fig. 5A,B, lanes 1 and
2). Furthermore, expression of either wild-type Yil113p or
Msg5p signi¢cantly reduces the activation of this MAPK
(Fig. 5A,B, lanes 3 and 4). Mutation of the active site cysteine
within all PTPs abolishes catalytic activity (see Fig. 2B). In
addition, PTPs carrying this inactivating mutation act as ‘sub-
strate traps’ forming a stable complex with their physiological
targets when expressed in mammalian cells [26,27]. Our results
show clearly that expression of mutant Yil113p causes the
accumulation of phosphorylated Slt2/Mpk1p even at the nor-
mal growth temperature (compare lanes 1 and 5 in Fig. 5A).
Furthermore, expression of Yil113pC140S signi¢cantly in-
creased the levels of phosphorylated Slt2/Mpk1p following
heat shock (compare lanes 2 and 6 in Fig. 5A). Msg5C319Sp
while unable to dephosphorylate Slt2/Mpk1p (compare lanes
4 and 6 Fig. 5B) did not appear to cause signi¢cant accumu-
lation of phosphorylated MAPK. None of the changes in the
levels of phosphorylated Slt2/Mpk1p which we observe are
due to heat shock-induced changes in the levels of the endog-
enous protein as veri¢ed by Western blotting using an anti-
body against Slt2/Mpk1p (Fig. 5C). We conclude that Yil113p
can dephosphorylate Slt2/Mpk1p in vivo and that the mutant
form of Yil113p is able to bind speci¢cally to phosphorylated
Slt2/Mpk1p, blocking its subsequent dephosphorylation by an
endogenous phosphatase.
4. Discussion
The YIL113w gene of S. cerevisiae encodes a putative pro-
tein phosphatase which is highly related to both mammalian
MKPs and the yeast dual-speci¢city MAPK phosphatase
Msg5p. In the present study we have demonstrated that
YIL113w encodes a catalytically active phosphatase which
shows speci¢c activity towards the ERK2 MAPK in vitro,
where it acts as a bona-¢de dual-speci¢city MAPK phospha-
tase. Furthermore, using the yeast two-hybrid assay to detect
protein^protein interactions we have shown that Yil113p in-
teracts speci¢cally with the Slt2/Mpk1p MAPK in S. cerevisi-
ae. Very recently, two systematic global surveys of protein^
protein complexes within the yeast proteome using mass spec-
trometry were published. In one of these, Yil113p was found
to be complexed with Slt2/Mpk1p [28] con¢rming both our
results and those of a preliminary global two-hybrid analysis
in which Yil113p also interacted with Slt2/Mpk1p [29]. Nei-
ther in our two-hybrid assays nor in any of these global sur-
veys was Yil113p able to interact with any of the other four
MAPKs of S. cerevisiae. This latter ¢nding coupled with our
observation that expression of wild-type Yil113p causes de-
phosphorylation of Slt2/Mpk1p in vivo while a substrate trap-
ping mutant of Yil113p enhances the phosphorylation of Slt2/
Mpk1p strongly suggests that the Yil113p phosphatase is a
speci¢c regulator of signalling through the Slt2/Mpk1p
MAPK pathway. This conclusion is supported by our own
¢ndings in which a YIL113w disruptant strain exhibited a
normal response to mating pheromone, indicating that
Yil113p is not involved in regulating the Fus3p MAPK
(M.C., unpublished observations) and by the results of a
study in which disruption of YIL113w alone or in combina-
tion with PTP2 and/or MSG5 was found to have no e¡ect on
phosphorylation of the Hog1p MAPK, indicating that
Yil113p is not involved in regulating the response to osmotic
stress in S. cerevisiae [7]. Finally, during preparation of this
manuscript an independent study by Hahn and Thiele which
also strongly supports a role for YIL113w in regulating the
Fig. 5. Yil113p dephosphorylates Slt2/Mpk1p in vivo. A: Western
blot analysis of phosphorylated Slt2/Mpk1p in yeast cells at the in-
dicated temperature using an antibody against phosphorylated
ERK2 MAPK (K-P-ERK2, upper panel). Cells contained either
empty pYES2 vector (lanes 1 and 2) or pYES2 expressing either
myc-tagged wild-type Yil113p (lanes 3 and 4) or Yil113pC140S (lanes
5 and 6). Expression of phosphatases was veri¢ed using the anti-
myc (9E10) monoclonal antibody (K-myc, lower panel). B: Western
blot analysis of phosphorylated Slt2/Mpk1p in yeast cells at the in-
dicated temperature using an antibody against phosphorylated
ERK2 MAPK (K-P-ERK2, upper panel). Cells contained either
empty pYES2 vector (lanes 1 and 2) or pYES2 expressing either
myc-tagged wild-type Msg5 (lanes 3 and 4) or Msg5pC319S (lanes 5
and 6). Expression of phosphatases was veri¢ed using the anti-myc
(9E10) monoclonal antibody (K-myc, lower panel). C: Western blot
of endogenous Slt2/Mpk1p protein in yeast cells grown at the indi-
cated temperature using a polyclonal antibody against Slt2/Mpk1p
(K-Mkp1p).
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Slt2/Mpk1p MAPK has appeared [30]. This shows that dele-
tion of YIL113w exacerbates growth defects due to overex-
pression of a constitutively active mutant of Slt2/Mpk1p, that
the heat shock-induced phosphorylation level of Slt2/Mpk1p
is elevated in this deletant when compared to a wild-type
strain and that heat shock-activated phospho-Slt2/Mpk1p is
dephosphorylated by recombinant Yil113p in vitro.
Mammalian dual-speci¢city MKPs contain two distinct do-
mains, a catalytic domain which contains the PTP active site
and an amino-terminal non-catalytic domain which carries
two diagnostic regions of sequence similarity with the cdc25
cell cycle regulatory phosphatase [31]. It is this latter domain
which mediates speci¢c interactions with MAPKs leading to
catalytic activation of these enzymes, thus determining sub-
strate selectivity [32]. Yil113p is a small protein when com-
pared to the mammalian MKPs and has sequence homology
only with the catalytic domain of these enzymes. We have
demonstrated that Yil113p interacts directly with the Slt2/
Mpk1p MAPK but, unlike the prototypic mammalian MKP
CL100/MKP-1, it does not undergo catalytic activation when
incubated with recombinant MAPKs. Interestingly, the mam-
malian dual-speci¢city phosphatase VHR, which also lacks an
amino-terminal non-catalytic domain, has also been shown to
interact with and dephosphorylate the ERK2 MAPK [33].
Furthermore, a Drosophila phosphatase (DMKP) of 203 ami-
no acids which is similar in sequence to VHR and also lacks
an amino-terminal non-catalytic domain has recently been
demonstrated to inactivate the Drosophila ERK and c-Jun-
N-terminal kinase MAPKs and also to inactivate Fus3p
when expressed in S. cerevisiae [34]. Yil113p may thus be a
member of an emerging subfamily of dual-speci¢city MKPs in
which substrate recognition is mediated by sequences which
reside within the catalytic domain and which do not require a
conformational change within the active site in order to de-
phosphorylate MAPKs.
The Slt2/Mpk1p MAPK cascade is composed of Bck1p
(MAPK kinase kinase), Mkk1p/Mkk2p (MAPK kinase) and
Slt2/Mpk1p (MAPK) and lies downstream of protein kinase-
C signalling [2]. The pathway is involved in the maintenance
of cell wall integrity and is activated in response to a variety
of stress conditions including heat shock [21] and hypotonic
shock [35]. Slt2/Mpk1p is also activated in response to mating
pheromone. However, this latter e¡ect is indirect and results
from re-organisation of the cell wall induced by the mating
pheromone pathway [36]. With respect to the regulation of
Slt2/Mpk1p by protein phosphatases it has been demonstrated
that the tyrosine-speci¢c phosphatases Ptp2p and Ptp3p neg-
atively regulate this kinase with Ptp2p playing the major role
[11]. Furthermore, the expression of Ptp2p, but not Ptp3p, is
increased in response to heat shock in a Slt2/Mpk1p depen-
dent manner suggesting that Ptp2p acts in a negative feedback
loop to regulate Slt2/Mpk1p. Slt2/Mpk1p is also targeted by
the dual-speci¢city phosphatase Msg5p [12]. Msg5p is induc-
ible by mating pheromone in a Fus3p dependent manner [10]
and thus may represent a point of crosstalk between these two
MAPK pathways.
In conclusion, we have demonstrated that the product of
the YIL113w gene of S. cerevisiae encodes a functional dual-
speci¢city MAPK phosphatase which interacts selectively with
and inactivates the Slt2/Mpk1p MAPK in vivo. Our results
add to the degree of complexity involved in the negative reg-
ulation of this pathway by adding Yil113p to the previously
characterised activities of Ptp2p,Ptp3p and Msg5p in regulat-
ing Slt2/Mpk1p. The challenge of future work will be to
understand how these di¡erent enzymes act in concert to de-
termine both the basal and induced levels of signalling
through this critical MAPK pathway.
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